title: [Clinical effects of FUT-187 in reflux esophagitis after gastrectomy].
abstract: FUT-187 was orally administered to 38 patients with postgastrectomy reflux esophagitis for 4 weeks. The drug reduced the chief subjective symptoms of reflux esophagitis, such as heartburn, chest pain, precordial pain, and dysphagia for solids in 78.1% of patients. Redness, edema and erosion were also reduced in 53.3% of patients as determined endoscopically. Overall, FUT-187 exhibited an excellent therapeutic effect on the reflux esophagitis which was refractory to conventional treatments.
authors.affiliation: Dept. of Surgical Oncology, Research Institute for Radiation Biology.
authors.forename: T
authors.initials: T
authors.lastname: Toge
authors.forename: T
authors.initials: T
authors.lastname: Hirai
authors.forename: W
authors.initials: W
authors.lastname: Takiyama
authors.forename: N
authors.initials: N
authors.lastname: Takashima
authors.forename: K
authors.initials: K
authors.lastname: Kawano
authors.forename: Y
authors.initials: Y
authors.lastname: Tamura
authors.forename: K
authors.initials: K
authors.lastname: Nishimawari
authors.forename: S
authors.initials: S
authors.lastname: Iwamori
authors.forename: K
authors.initials: K
authors.lastname: Nakanishi
authors.forename: H
authors.initials: H
authors.lastname: Kono
mesh_terms: D000284:Administration, Oral; D000368:Aged; D004942:Esophagitis, Peptic / Q000188:drug therapy* / Q000209:etiology; D005260:Female; D005743:Gastrectomy / Q000009:adverse effects*; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications
chemical_list: D007093:Imidazoles; C058875:sepimostate mesilate